openPR Logo
Press release

Tyrosine Kinase Inhibitors - Pipeline Insights 2017

10-25-2017 01:28 PM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Tyrosine kinase Inhibitors-Pipeline Insights 2017

Tyrosine kinase Inhibitors-Pipeline Insights 2017

The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline tyrosine kinase inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

View Report: https://www.arizton.com/reports/pharma-pipeline-analysis/tyrosine-kinase-inhibitors-pipeline-insights-2017

The report profiles key players in developing potential tyrosine kinase drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Few of the key marketed tyrosine kinase inhibitors include Dasatinib (Sprycel), Erlotinib (Tarceva), Gefitinib (Iressa), Imatinib (Gleevec). Lapatinib (Tykerb), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent).

Over the past two decades, research studies have proved its efficacy for mitigation and control of non-cancerous diseases too. Thus research activity on use of inhibitors for various diseases such as Parkinson's disease and chronic obstructive pulmonary disorder is gradually increasing. The growing availability of these agents has enabled the pharmaceutical companies to develop new combination molecules which have the capacity to provide greater insight into the body’s acceptance of inhibitors so as to develop more effective therapies.

More recently, few molecules have been developed that inhibits tyrosine kinase these agents are in various stages of clinical development. The tyrosine kinase inhibitors pipeline has more than 15 molecules and is expected to achieve the regulatory approval in the near future, few of which are Oncoprex (CNVN202), ORS-1006, JNJ 49095397, RV-568, AP32788, APTO-500, and transtinib. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage. Few of the companies which are involved in the development of tyrosine kinase inhibitor include IL-Yang Pharm, SRI, Sareum, Genprex, Arrien, J&J, and Takeda.

Reasons to Buy

To gain erudite insights about the Tyrosine Kinase inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

View Report: https://www.arizton.com/reports/pharma-pipeline-analysis/tyrosine-kinase-inhibitors-pipeline-insights-2017

Related Reports

1) Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

2) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Inhibitors - Pipeline Insights 2017 here

News-ID: 785531 • Views: 499

More Releases from Arizton Advisory & Intelligence

Iran Construction Equipment Market to Reach $411 million by 2028.
According to Arizton latest research report, the Iran construction equipment market is expected to grow at a CAGR of 7%. Government investments in road construction, infrastructure development, housing projects, smart cities, and the development of Eastern and Southern Corridors of the country expect to have a higher impact on the demand for excavators and backhoe loaders than other earthmoving equipment in Iran. In 2022, the Iranian government announced 48
Thailand Data Center Market to Reach $1 Billion by 2027. Around 38.4 MW Power Ca …
According to Arizton latest research report, Thailand data center market is expected to grow at a CAGR of 7.7% during 2021-2027. Digitalization driven by the COVID-19 pandemic, deployment of 5G technology, and the introduction of the Personal Data Protection Law (PDPL) are some factors that will drive the Thailand data center market as it will lead to increase in the demand for the data center facilities. The Thailand data
The U.S. Commercial Lawn Mower Market to Reach $2.6 Billion by 2027| Availabilit …
According to Arizton's latest research report, the US commercial lawn mower market is expected to grow at a CAGR of 4.67% during 2021-2027. Many companies such as Husqvarna are bringing equipment such as robotic lawn mowers to the next level by equipping their next generation of robotic lawn mowers with connected technology and services. Hence, the constant efforts for the development of new features & technology for lawn mowers are
The Global Regulatory Affairs Outsourcing Market is Expected to Reach $16.8 Bill …
The global regulatory affairs outsourcing market was valued at $8.2 billion in 2021 and is expected to reach $16.8 billion by 2027. According to the latest research report by Arizton, the global regulatory affairs outsourcing market is expected to grow at a CAGR of 12.73% during 2022-2027. The increasing use of digital platforms, changing regulatory landscape, and the emergence of virtual trials & virtual communication are the major factors in

All 5 Releases


More Releases for Pipeline

Pipeline of Batten Disease Market Pipeline Review, H2 2017
"The Report Batten Disease - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known
Cluster Headache Syndrome Pipeline Review H2, 2017 - Pharmaceutical Pipeline Gui …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome Pipeline Review, H2 2017, provides an overview of the Cluster Headache Syndrome pipeline landscape. Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender.
Thalassemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thalassemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms
Cachexia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Cachexia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cachexia – Pipeline Review, H1 2017, provides an overview of the Cachexia (Musculoskeletal Disorders) pipeline landscape. Cachexia is the dramatic weight loss and muscle atrophy seen in patients with chronic illness including type I diabetes, multiple sclerosis,
Ependymoma - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Ependymoma - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma – Pipeline Review, H1 2017, provides an overview of the Ependymoma (Oncology) pipeline landscape. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in
Fibrosarcoma - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fibrosarcoma - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma – Pipeline Review, H1 2017, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain